Greve Tobias, Ehret Felix, Hofmann Theresa, Thorsteinsdottir Jun, Dorn Franziska, Švigelj Viktor, Resman-Gašperšič Anita, Tonn Joerg-Christian, Schichor Christian, Muacevic Alexander
Department of Neurosurgery, University Hospital, LMU Munich, Munich, Germany.
European Cyberknife Center Munich-Grosshadern, Munich, Germany.
Front Oncol. 2021 Mar 9;10:608750. doi: 10.3389/fonc.2020.608750. eCollection 2020.
CyberKnife offers CT- and MRI-based treatment planning without the need for stereotactically acquired DSA. The literature on CyberKnife treatment of cerebral AVMs is sparse. Here, a large series focusing on cerebral AVMs treated by the frameless CyberKnife stereotactic radiosurgery (SRS) system was analyzed.
In this retrospective study, patients with cerebral AVMs treated by CyberKnife SRS between 2005 and 2019 were included. Planning was MRI- and CT-based. Conventional DSA was not coregistered to the MRI and CT scans used for treatment planning and was only used as an adjunct. Obliteration dynamics and clinical outcome were analyzed.
215 patients were included. 53.0% received SRS as first treatment; the rest underwent previous surgery, embolization, SRS, or a combination. Most AVMs were classified as Spetzler-Martin grade I to III (54.9%). Hemorrhage before treatment occurred in 46.0%. Patients suffered from headache (28.8%), and seizures (14.0%) in the majority of cases. The median SRS dose was 18 Gy and the median target volume was 2.4 cm³. New neurological deficits occurred in 5.1% after SRS, with all but one patient recovering. The yearly post-SRS hemorrhage incidence was 1.3%. In 152 patients who were followed-up for at least three years, 47.4% showed complete AVM obliteration within this period. Cox regression analysis revealed Spetzler-Martin grade (P = 0.006) to be the only independent predictor of complete obliteration.
Although data on radiotherapy of AVMs is available, this is one of the largest series, focusing exclusively on CyberKnife treatment. Safety and efficacy compared favorably to frame-based systems. Non-invasive treatment planning, with a frameless SRS robotic system might provide higher patient comfort, a less invasive treatment option, and lower radiation exposure.
射波刀可提供基于CT和MRI的治疗计划,无需立体定向血管造影(DSA)。关于射波刀治疗脑动静脉畸形(AVM)的文献较少。本文分析了一系列采用无框架射波刀立体定向放射外科(SRS)系统治疗脑AVM的病例。
本回顾性研究纳入了2005年至2019年期间接受射波刀SRS治疗的脑AVM患者。治疗计划基于MRI和CT。传统DSA未与用于治疗计划的MRI和CT扫描进行配准,仅作为辅助手段使用。分析了闭塞动态和临床结果。
共纳入215例患者。53.0%的患者首次接受SRS治疗;其余患者曾接受过手术、栓塞、SRS或联合治疗。大多数AVM被分类为Spetzler-Martin I至III级(54.9%)。46.0%的患者在治疗前发生过出血。大多数患者有头痛(28.8%)和癫痫发作(14.0%)症状。SRS的中位剂量为18 Gy,中位靶体积为2.4 cm³。SRS后5.1%的患者出现新的神经功能缺损,除1例患者外均恢复。SRS后每年的出血发生率为1.3%。在152例至少随访三年的患者中,47.4%在此期间显示AVM完全闭塞。Cox回归分析显示,Spetzler-Martin分级(P = 0.006)是完全闭塞的唯一独立预测因素。
尽管已有关于AVM放射治疗的数据,但这是专注于射波刀治疗的最大系列之一。与基于框架的系统相比,其安全性和有效性良好。使用无框架SRS机器人系统进行非侵入性治疗计划,可能会为患者带来更高的舒适度、侵入性更小的治疗选择以及更低的辐射暴露。